You are here

  • Home
  • Archive
  • Volume 13, Issue 1
  • Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

Citation Tools

Article menu
Mental health
Protocol
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sass MR, Danielsen AA, Köhler-Forsberg O, et al
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
BMJ Open 2023;13:e068652. doi: 10.1136/bmjopen-2022-068652